Phase 3 Recruiting Academic/Other
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …
Sponsor: NRG Oncology
NCT ID: NCT05946213
Sites in Utah: - American Fork Hospital / Huntsman Intermountain Cancer Center — American Fork, Utah
- Sandra L Maxwell Cancer Center — Cedar City, Utah
- Farmington Health Center — Farmington, Utah
- Logan Regional Hospital — Logan, Utah
- Intermountain Medical Center — Murray, Utah
Phase 3 Recruiting Network
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03678025
Sites in Utah: - American Fork Hospital / Huntsman Intermountain Cancer Center — American Fork, Utah
- Sandra L Maxwell Cancer Center — Cedar City, Utah
- Logan Regional Hospital — Logan, Utah
- Intermountain Medical Center — Murray, Utah
- McKay-Dee Hospital Center — Ogden, Utah
Phase 3 Recruiting Network
This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Sites in Utah: - Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding docetaxel to hormonal therapy and apalutamide versus hormonal therapy and apalutamide alone in treating patients with prostate cancer that has spread from where it first started (primary s…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06931340
Sites in Utah: - Intermountain Medical Center — Murray, Utah
- LDS Hospital — Salt Lake City, Utah
- Saint George Regional Medical Center — St. George, Utah
Phase 3 Recruiting Industry
The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC.
Sponsor: AstraZeneca
NCT ID: NCT06120491
Sites in Utah: - Research Site — Salt Lake City, Utah
- Research Site — Salt Lake City, Utah
- Research Site — St. George, Utah
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate Cancer.
Sponsor: Celgene
NCT ID: NCT06764485
Sites in Utah: - Intermountain Medical Center — Murray, Utah
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in combination with best supportive care (BSC) as compared to placebo with…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07164443
Sites in Utah: - Utah Cancer Specialists — Salt Lake City, Utah
Phase 3 Recruiting Industry
The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in particip…
Sponsor: AstraZeneca
NCT ID: NCT06952803
Sites in Utah: - Research Site — Salt Lake City, Utah
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of 177Lu-TLX591 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with Androgen Receptor Pathway Inhibitor Treatment
Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited
NCT ID: NCT06520345
Sites in Utah: - Intermountain Health — Murray, Utah
- Intermountain Health — Salt Lake City, Utah
Phase 1, Phase 2 Recruiting Industry
IDE574 is a synthetically manufactured small molecule inhibitor that co-targets the lysine acetyltransferase enzymes KAT6 and KAT7. The purpose of this study is to evaluate the safety, preliminary efficacy, pharmacokinetics (PK), and pharm…
Sponsor: IDEAYA Biosciences
NCT ID: NCT07540572
Sites in Utah: - START Mountain Region, LLC — West Valley City, Utah
Phase 1, Phase 2 Recruiting Industry
ANDROMEDA is a first-in-human, Phase I/II, open-label, multicenter study of AZD9750 in participants with metastatic prostate cancer. The trial evaluates safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary efficacy of A…
Sponsor: AstraZeneca
NCT ID: NCT07336446
Sites in Utah: - Research Site — Salt Lake City, Utah
Phase 1, Phase 2 Recruiting Industry
This is a multicenter, open-label FIH, Phase 1a (dose escalation), Phase 1b (dose expansion) and Phase 2 study in patients with advanced metastatic solid tumors refractory to standard treatment.
Sponsor: MBrace Therapeutics
NCT ID: NCT07145255
Sites in Utah: - START, Mountain Region — West Valley City, Utah
Phase 2 Recruiting Academic/Other
This trial will evaluate whether the immune-sensitizing effects of immunotherapy (Pembrolizumab) and radiation with or without a PARP-inhibitor (Olaparib) will increase the effects of immunotherapy in men with high-risk localized prostate …
Sponsor: Zin W Myint
NCT ID: NCT05568550
Sites in Utah: - Huntsman Cancer Institute — Salt Lake City, Utah
Phase 2 Recruiting Academic/Other
The purpose of this study is to determine how well the study drug XL092 is helping to treat a participant's cancer after 16 weeks of treatment. Researchers will also look at how safe the XL092 is and how well the XL092 is working. XL092 is…
Sponsor: University of Utah
NCT ID: NCT06568562
Sites in Utah: - Huntsman Cancer Institute at University of Utah — Salt Lake City, Utah
Phase 2 Recruiting Academic/Other
The purpose of this study is to evaluate intermittent relugolix + androgen receptor pathway inhibitor (ARPI) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) achieving optimal PSA response.
Sponsor: University of Utah
NCT ID: NCT07216248
Sites in Utah: - Huntsman Cancer Institute at University of Utah — Salt Lake City, Utah
Phase 2 Recruiting Academic/Other
The goal of this clinical trial is to test the anti-tumor activity of bortezomib in participants with Metastatic Castration Resistant Prostate Cancer (mCRPC) with PTEN Deletion. The main question\[s\] it aims to answer is if the use of bor…
Sponsor: University of Utah
NCT ID: NCT06029998
Sites in Utah: - Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
Phase 1 Recruiting Industry
The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab.
Sponsor: IDEAYA Biosciences
NCT ID: NCT05787587
Sites in Utah: - START Mountain Region — West Valley City, Utah
Phase 1 Recruiting Industry
The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tu…
Sponsor: MacroGenics
NCT ID: NCT06242470
Sites in Utah: - START Mountain Region — West Valley City, Utah
Phase 1 Recruiting Industry
The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select solid tumors.
Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
NCT ID: NCT07517198
Sites in Utah: - START Mountain Region — West Valley City, Utah
Phase 1 Recruiting Academic/Other
This is an open-label, phase 1b dose-escalation study of cabozantinib in combination with 177Lu-PSMA-617 in subjects with mCRPC. The primary hypothesis is that cabozantinib with 177Lu-PSMA will be safe and have efficacy in patients with mC…
Sponsor: University of Utah
NCT ID: NCT05613894
Sites in Utah: - Huntsman Cancer Institute at University of Utah — Salt Lake City, Utah
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Utah: - Massive Bio SYNERGY-AI site — Salt Lake City, Utah
NA Recruiting Academic/Other
People with prostate cancer may have a decreased quality of life due to the cancer itself and due to a lifesaving cancer treatment. Physical therapy, including regular exercise, helps patients with cancer to reduce disease symptoms and imp…
Sponsor: University of Utah
NCT ID: NCT07032584
Sites in Utah: - University of Utah Huntsman Cancer Institute — Salt Lake City, Utah
NA Recruiting Academic/Other
Prostate cancer has a significant impact on patient quality of life (QoL) directly, as well as through the management of localized disease (such as surgery and radiation-related incontinence, erectile dysfunction, and bowel dysfunction), a…
Sponsor: University of Utah
NCT ID: NCT07093177
Sites in Utah: - Huntsman Cancer Institute at University of Utah — Salt Lake City, Utah